Analysts’ Viewpoint
Increase in prevalence of eye disorders and diseases is driving the global ophthalmic drugs market. Surge in incidence of eye conditions, such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy, due to aging population and changing lifestyles has led to higher demand for effective ophthalmic drugs to manage and treat these conditions. Furthermore, rise in healthcare expenditure and increase in awareness about eye health are likely to bolster global ophthalmic drugs market growth.
Advancements in technology and introduction of gene & stem cell therapies in ophthalmology offer lucrative opportunities to market players. Pharmaceutical companies are investing significantly in R&D to develop innovative drugs with enhanced therapeutic efficacy and improved delivery systems.
However, stringent regulatory requirements, high cost associated with drug development & clinical trials, availability of low-cost generic drugs, and high risk of adverse effects of drugs are likely to hamper the ophthalmic drugs industry growth during the forecast period.
Ophthalmic drugs are a category of pharmaceuticals specifically designed for the treatment, management, and prevention of eye disorders and diseases. These drugs are formulated to be administered directly to the eyes or their surrounding structures, typically in the form of eye drops, ointments, gels, or injections.
The field of ophthalmology encompasses a range of conditions, including but not limited to glaucoma, macular degeneration, diabetic retinopathy, dry eye, conjunctivitis, and ocular infections. Ophthalmic drugs are developed to address the specific needs of these conditions and provide therapeutic relief, improve vision, or slow down disease progression.
There are several categories of ophthalmic drugs, each targeting different aspects of eye health and functioning. Anti-inflammatory drugs are used to reduce inflammation in the eyes and provide relief from symptoms such as redness, swelling, and pain.
Anti-infective drugs, such as antibiotics and antivirals, are utilized to treat bacterial, viral, and fungal infections affecting the eyes. Anti-glaucoma drugs are designed to lower intraocular pressure, a major risk factor for glaucoma, to prevent further damage to the optic nerve. Anti-allergy drugs help manage allergic reactions that affect the eyes, such as itching, watering, and redness.
Development of ophthalmic drugs involves extensive research and clinical trials to ensure safety, efficacy, and proper delivery to the targeted ocular tissues. Formulation techniques are used to optimize drug delivery, such as creating sustained-release formulations that prolong drug release and reduce the frequency of administration. Combination therapies, which involve multiple active ingredients in a single formulation, are also being explored to enhance treatment outcomes and convenience for patients.
The global is driven by aging population, rise in prevalence of eye diseases, technological advancements, and surge in healthcare expenditure. Incidence of age-related eye disorders, such as cataracts and macular degeneration, is likely to increase due to rise in global geriatric population, which, in turn, is driving the demand for ophthalmic drugs.
Technological advancements in drug delivery systems, such as nanoparticles and implants, offer new avenues for targeted and sustained drug delivery to the eyes. Furthermore, increase in healthcare spending and rise in awareness about eye health are propelling global ophthalmic drugs market demand.
Rise in prevalence of ophthalmic disorders and diseases is one of the key drivers of the ophthalmic drugs market size. Eye disorders, such as cataract, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and dry eye syndrome, are becoming more common.
This is ascribed to several factors such as aging population, unhealthy lifestyle choices, and increase in incidence of chronic diseases such as diabetes. If untreated, these eye conditions could cause vision impairment or even blindness, leading to rise in prevalence of the conditions.
According to the World Health Organization (WHO), over 2.2 billion people globally have some form of visual impairment or blindness. Of these, 1 billion people have a condition that could have been prevented or is yet to be treated. WHO estimates the number of people with vision impairment to triple by 2050, with the greatest increase in low- and middle-income countries.
According to the American Academy of Ophthalmology, the prevalence of age-related macular degeneration (AMD) is expected to increase from 196 million people in 2020 to 288 million people in 2040, an increase of 47% in just 20 years.
According to The International Myopia Institute, currently, around 30% of the world’s population has myopia and is expected to reach 50%, which is a staggering 5 billion people. The Glaucoma Research Foundation states that about 3 million individuals in the U.S. are affected by glaucoma, and the number is anticipated to rise to 4.2 million by 2030.
Surge in awareness about eye health and the importance of early diagnosis and treatment is another key factor driving the global ophthalmic drugs market share. Awareness about eye health is increasing through education and outreach programs. For instance, the World Sight Day is an annual event held on the second Thursday of October to raise awareness about the importance of eye health.
Organizations such as the American Academy of Ophthalmology and the International Agency for the Prevention of Blindness run public education campaigns to spread awareness about eye health and encourage people to have regular eye check-ups.
Non-Governmental Organizations (NGOs) such as Orbis International, Sight Savers, and the International Agency for the Prevention of Blindness (IAPB) are working to increase awareness about eye health and provide eye care services to underserved populations.
In the U.S., the National Eye Institute runs the Healthy Vision Month campaign every May to encourage people to take care of their eyes and have regular eye exams.
The Fred Hollows Foundation, an international development organization, works to prevent and treat blindness and other vision problems in developing countries. The foundation provides training to local eye care workers and advocates for better eye health policies.
Governments and healthcare organizations across the world are investing in campaigns and initiatives to educate the public about the significance of regular eye checkups and timely intervention. This has led to increase in the number of patients seeking ophthalmic drugs for treatment.
In terms of therapeutic class, the anti-VEGF segment accounted for major share of the global market in 2022. This is ascribed to increase in prevalence of ophthalmic diseases, including diabetic retinopathy, macular edema, age-related macular degeneration (AMD), and retinal vein occlusion, combined with surge in global geriatric population that is exposed to the risk of developing the condition.
Novel product launches across the globe are expected to fuel the segment. For example, in December 2022, Valitor announced a presentation on Multivalent Polymer Technology and Novel Anti-VEGF Antibody Conjugate Platform at the Ophthalmology Innovation Source Summit.
Based on indication, retinal disorders is projected to be a lucrative segment of the global ophthalmic drugs market during the forecast period.
Retinal disorders, such as diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion (RVO), are becoming more common across the world. This has led to increase in demand for effective treatments for these conditions.
Availability of promising pipeline products is anticipated to propel the retinal disorders segment during the analysis period. Moreover, nearly 11 million people in the U.S. have some form of AMD, while 1.1 million people, or 10%, have wet AMD. Nearly 200,000 new cases of wet AMD are diagnosed every year across the U.S. Diabetic retinopathy impacts nearly 7.7 million people in the country. The number is expected to increase to 11.3 million by 2030.
In terms of dosage form, the eye drops segment is projected to dominate the global ophthalmic drugs market during the forecast period.
Increase in global geriatric population, which is more susceptible to eye illnesses, and surge in number of bacterial infection cases in youngsters are anticipated to propel the eye drops segment in the next few years.
Several novel innovations in eye drops, such as nanoparticle-based eye drops, preservative-free eye drops, and smart eye drops, are driving the segment. For instance, in August 2022, Alcon announced new addition to its advanced portfolio of dry-eye medications. The new ‘SYSTANE COMPLETE’ Preservative-Free eye drops is an all-in-one solution available in multi-dose and easy-to-use bottle.
In October 2021, Novaliq, a biopharmaceutical company specializing in innovative ocular therapeutics using their proprietary EyeSol technology, declared the adoption and implementation of a quality management system aligned with Annex IX, Chapter I of the EU Medical Device Regulation (MDR). This system was applied for assessing the compliance of their medical devices, namely NovaTears, NovaTears+Omega-3, and EvoTears OMEGA.
According to ophthalmic drugs market trends, North America is a significant market for ophthalmic drugs, with the U.S. being the largest contributor to market revenue. Increase in prevalence of common eye disorders and eye diseases across the region is one of the major factors driving the market during the forecast period.
According to the CDC, in the U.S. alone, around 12 million people aged 40 and older suffer from vision impairment, with about a million suffering from blindness.
In Canada, 5.5 million Canadians (1 in 7) have vision threatening eye conditions. Additionally, introduction of new and innovative ophthalmic drugs & therapies, increase in healthcare expenditure, and rise in awareness about eye health are propelling the market in the country.
Strong presence of prominent players, including Regeneron Pharmaceuticals Inc., Allergan/AbbVie, and Alcon Vision LLC, and their effective strategies are expected to drive the market in the region. Moreover, startup companies operating in the U.S. are entering into partnerships. For instance, in February 2023, Eyenovia and Formosa partnered for new ophthalmic therapeutics.
The market in Asia Pacific is projected to expand at the fastest CAGR during the forecast period. Expansion of the market in the region can be attributed to high disease prevalence, emergence of local companies, and presence of a large patient pool.
Asia Pacific has the largest patient base. Multiple strategic initiatives implemented by key drug manufacturers are projected to bolster market expansion in the region.
In July 2018, Novotech, Asia Pacific-centered global biotech CRO, announced partnership with the Asian Eye Institute, Inc. (AEI), the Philippines-based prominent eye center, in order to facilitate rapid and high-quality feasibility, recruitment processes, and start-up for its ophthalmology clients.
This report provides profiles of leading players operating in the global ophthalmic drugs market. These include AbbVie, Inc., Alcon Vision LLC, Bausch Health Companies, Inc., Bayer AG, Coherus BioSciences, F. Hoffmann-La Roche Ltd., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
These players engage in mergers & acquisitions, strategic collaborations, and new product launches to expand presence and gain market share.
The ophthalmic drugs industry research report profiles the top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements.
|
Attribute |
Detail |
|---|---|
|
Size in 2022 |
US$ 31.4 Bn |
|
Forecast (Value) in 2031 |
More than US$ 52.8 Bn |
|
Growth Rate (CAGR) |
6.2% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2022 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 31.4 Bn in 2022
It is projected to reach more than US$ 52.8 Bn by 2031
It is anticipated to expand at a CAGR of 6.2% from 2023 to 2031
The anti-VEGF agents segment accounted for the largest market share in 2022
North America is expected to account for the leading market share during the forecast period.
AbbVie, Inc., Alcon Vision LLC, Bausch Health Companies, Inc., Bayer AG, Coherus BioSciences, F. Hoffmann-La Roche Ltd., Novartis Pharmaceuticals Corporation, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Santen, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are the leading players in the global market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ophthalmic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ophthalmic Drugs Market Volume Forecast, by Dosage Form, 2017-2031
5. Key Insights
5.1. Disease Prevalence & Incidence rate globally with key countries
5.2. Pipeline Analysis
5.3. Key Industry Events
5.4. Covid-19 Pandemic Impact on the Industry
6. Global Ophthalmic Drugs Market Analysis and Forecast, by Therapeutic Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapeutic Class, 2017-2031
6.3.1. Anti-VEGF Agents
6.3.2. Anti-glaucoma Drugs
6.3.2.1. Alpha Agonist
6.3.2.2. Beta Blockers
6.3.2.3. Prostaglandin Analogs
6.3.2.4. Combined Medication
6.3.2.5. Others
6.3.3. Anti-inflammatory Drugs
6.3.3.1. Steroids
6.3.3.2. NSAIDs
6.3.4. Anti-infective Drugs
6.3.4.1. Anti-bacterial Drugs
6.3.4.2. Anti-fungal Drugs
6.3.4.3. Others
6.3.5. Anti-allergy Drugs
6.3.6. Others
6.4. Market Attractiveness Analysis, by Therapeutic Class
7. Global Ophthalmic Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017-2031
7.3.1. Dry Eye
7.3.2. Glaucoma
7.3.3. Infection/Inflammation
7.3.4. Retinal Disorders
7.3.4.1. Wet AMD
7.3.4.2. Dry AMD
7.3.4.3. Diabetic Retinopathy
7.3.4.4. Others
7.3.5. Allergy
7.3.6. Uveitis
7.3.7. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Ophthalmic Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017-2031
8.3.1. Topical
8.3.2. Local Ocular (intravitreal)
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Ophthalmic Drugs Market Analysis and Forecast, by Product Type
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Product Type, 2017-2031
9.3.1. Prescription
9.3.2. OTC
9.4. Market Attractiveness Analysis, by Product Type
10. Global Ophthalmic Drugs Market Analysis and Forecast, by Dosage Form
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Dosage Form, 2017-2031
10.3.1. Eye Drops
10.3.2. Eye Solutions & Suspensions
10.3.3. Capsules & Tablets
10.3.4. Gels
10.3.5. Ointments
10.3.6. Others
10.4. Market Attractiveness Analysis, by Dosage Form
11. Global Ophthalmic Drugs Market Analysis and Forecast, by Distribution Channel
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Attractiveness Analysis, by Distribution Channel
12. Global Ophthalmic Drugs Market Analysis and Forecast, by Region
12.1. Key Findings
12.2. Market Value Forecast, by Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness Analysis, by Region
13. North America Ophthalmic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutic Class, 2017-2031
13.2.1. Anti-VEGF Agents
13.2.2. Anti-glaucoma Drugs
13.2.2.1. Alpha Agonist
13.2.2.2. Beta Blockers
13.2.2.3. Prostaglandin Analogs
13.2.2.4. Combined Medication
13.2.2.5. Others
13.2.3. Anti-inflammatory Drugs
13.2.3.1. Steroids
13.2.3.2. NSAIDs
13.2.4. Anti-infective Drugs
13.2.4.1. Anti-bacterial Drugs
13.2.4.2. Anti-fungal Drugs
13.2.4.3. Others
13.2.5. Anti-allergy Drugs
13.2.6. Others
13.3. Market Value Forecast, by Indication, 2017-2031
13.3.1. Dry Eye
13.3.2. Glaucoma
13.3.3. Infection/Inflammation
13.3.4. Retinal Disorders
13.3.4.1. Wet AMD
13.3.4.2. Dry AMD
13.3.4.3. Diabetic Retinopathy
13.3.4.4. Others
13.3.5. Allergy
13.3.6. Uveitis
13.3.7. Others
13.4. Market Value Forecast, by Route of Administration, 2017-2031
13.4.1. Topical
13.4.2. Local Ocular (intravitreal)
13.4.3. Others
13.5. Market Value Forecast, by Product Type, 2017-2031
13.5.1. Prescription
13.5.2. OTC
13.6. Market Value Forecast, by Dosage Form, 2017-2031
13.6.1. Eye Drops
13.6.2. Eye Solutions & Suspensions
13.6.3. Capsules & Tablets
13.6.4. Gels
13.6.5. Ointments
13.6.6. Others
13.7. Market Value Forecast, by Distribution Channel, 2017-2031
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.8. Market Value Forecast, by Country, 2017-2031
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Therapeutic Class
13.9.2. By Indication
13.9.3. By Route of Administration
13.9.4. By Product Type
13.9.5. By Dosage Form
13.9.6. By Distribution Channel
13.9.7. By Country
14. Europe Ophthalmic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Therapeutic Class, 2017-2031
14.2.1. Anti-VEGF Agents
14.2.2. Anti-glaucoma Drugs
14.2.2.1. Alpha Agonist
14.2.2.2. Beta Blockers
14.2.2.3. Prostaglandin Analogs
14.2.2.4. Combined Medication
14.2.2.5. Others
14.2.3. Anti-inflammatory Drugs
14.2.3.1. Steroids
14.2.3.2. NSAIDs
14.2.4. Anti-infective Drugs
14.2.4.1. Anti-bacterial Drugs
14.2.4.2. Anti-fungal Drugs
14.2.4.3. Others
14.2.5. Anti-allergy Drugs
14.2.6. Others
14.3. Market Value Forecast, by Indication, 2017-2031
14.3.1. Dry Eye
14.3.2. Glaucoma
14.3.3. Infection/Inflammation
14.3.4. Retinal Disorders
14.3.4.1. Wet AMD
14.3.4.2. Dry AMD
14.3.4.3. Diabetic Retinopathy
14.3.4.4. Others
14.3.5. Allergy
14.3.6. Uveitis
14.3.7. Others
14.4. Market Value Forecast, by Route of Administration, 2017-2031
14.4.1. Topical
14.4.2. Local Ocular (intravitreal)
14.4.3. Others
14.5. Market Value Forecast, by Product Type, 2017-2031
14.5.1. Prescription
14.5.2. OTC
14.6. Market Value Forecast, by Dosage Form, 2017-2031
14.6.1. Eye Drops
14.6.2. Eye Solutions & Suspensions
14.6.3. Capsules & Tablets
14.6.4. Gels
14.6.5. Ointments
14.6.6. Others
14.7. Market Value Forecast, by Distribution Channel, 2017-2031
14.7.1. Hospital Pharmacies
14.7.2. Retail Pharmacies
14.7.3. Online Pharmacies
14.8. Market Value Forecast, by Country/Sub-region, 2017-2031
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Therapeutic Class
14.9.2. By Indication
14.9.3. By Route of Administration
14.9.4. By Product Type
14.9.5. By Dosage Form
14.9.6. By Distribution Channel
14.9.7. By Country/Sub-region
15. Asia Pacific Ophthalmic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Therapeutic Class, 2017-2031
15.2.1. Anti-VEGF Agents
15.2.2. Anti-glaucoma Drugs
15.2.2.1. Alpha Agonist
15.2.2.2. Beta Blockers
15.2.2.3. Prostaglandin Analogs
15.2.2.4. Combined Medication
15.2.2.5. Others
15.2.3. Anti-inflammatory Drugs
15.2.3.1. Steroids
15.2.3.2. NSAIDs
15.2.4. Anti-infective Drugs
15.2.4.1. Anti-bacterial Drugs
15.2.4.2. Anti-fungal Drugs
15.2.4.3. Others
15.2.5. Anti-allergy Drugs
15.2.6. Others
15.3. Market Value Forecast, by Indication, 2017-2031
15.3.1. Dry Eye
15.3.2. Glaucoma
15.3.3. Infection/Inflammation
15.3.4. Retinal Disorders
15.3.4.1. Wet AMD
15.3.4.2. Dry AMD
15.3.4.3. Diabetic Retinopathy
15.3.4.4. Others
15.3.5. Allergy
15.3.6. Uveitis
15.3.7. Others
15.4. Market Value Forecast, by Route of Administration, 2017-2031
15.4.1. Topical
15.4.2. Local Ocular (intravitreal)
15.4.3. Others
15.5. Market Value Forecast, by Product Type, 2017-2031
15.5.1. Prescription
15.5.2. OTC
15.6. Market Value Forecast, by Dosage Form, 2017-2031
15.6.1. Eye Drops
15.6.2. Eye Solutions & Suspensions
15.6.3. Capsules & Tablets
15.6.4. Gels
15.6.5. Ointments
15.6.6. Others
15.7. Market Value Forecast, by Distribution Channel, 2017-2031
15.7.1. Hospital Pharmacies
15.7.2. Retail Pharmacies
15.7.3. Online Pharmacies
15.8. Market Value Forecast, by Country/Sub-region, 2017-2031
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Therapeutic Class
15.9.2. By Indication
15.9.3. By Route of Administration
15.9.4. By Product Type
15.9.5. By Dosage Form
15.9.6. By Distribution Channel
15.9.7. By Country/Sub-region
16. Latin America Ophthalmic Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Therapeutic Class, 2017-2031
16.2.1. Anti-VEGF Agents
16.2.2. Anti-glaucoma Drugs
16.2.2.1. Alpha Agonist
16.2.2.2. Beta Blockers
16.2.2.3. Prostaglandin Analogs
16.2.2.4. Combined Medication
16.2.2.5. Others
16.2.3. Anti-inflammatory Drugs
16.2.3.1. Steroids
16.2.3.2. NSAIDs
16.2.4. Anti-infective Drugs
16.2.4.1. Anti-bacterial Drugs
16.2.4.2. Anti-fungal Drugs
16.2.4.3. Others
16.2.5. Anti-allergy Drugs
16.2.6. Others
16.3. Market Value Forecast, by Indication, 2017-2031
16.3.1. Dry Eye
16.3.2. Glaucoma
16.3.3. Infection/Inflammation
16.3.4. Retinal Disorders
16.3.4.1. Wet AMD
16.3.4.2. Dry AMD
16.3.4.3. Diabetic Retinopathy
16.3.4.4. Others
16.3.5. Allergy
16.3.6. Uveitis
16.3.7. Others
16.4. Market Value Forecast, by Route of Administration, 2017-2031
16.4.1. Topical
16.4.2. Local Ocular (intravitreal)
16.4.3. Others
16.5. Market Value Forecast, by Product Type, 2017-2031
16.5.1. Prescription
16.5.2. OTC
16.6. Market Value Forecast, by Dosage Form, 2017-2031
16.6.1. Eye Drops
16.6.2. Eye Solutions & Suspensions
16.6.3. Capsules & Tablets
16.6.4. Gels
16.6.5. Ointments
16.6.6. Others
16.7. Market Value Forecast, by Distribution Channel, 2017-2031
16.7.1. Hospital Pharmacies
16.7.2. Retail Pharmacies
16.7.3. Online Pharmacies
16.8. Market Value Forecast, by Country/Sub-region,2017-2031
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Therapeutic Class
16.9.2. By Indication
16.9.3. By Route of Administration
16.9.4. By Product Type
16.9.5. By Dosage Form
16.9.6. By Distribution Channel
16.9.7. By Country/Sub-region
17. Middle East & Africa Ophthalmic Drugs Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast, by Therapeutic Class, 2017-2031
17.2.1. Anti-VEGF Agents
17.2.2. Anti-glaucoma Drugs
17.2.2.1. Alpha Agonist
17.2.2.2. Beta Blockers
17.2.2.3. Prostaglandin Analogs
17.2.2.4. Combined Medication
17.2.2.5. Others
17.2.3. Anti-inflammatory Drugs
17.2.3.1. Steroids
17.2.3.2. NSAIDs
17.2.4. Anti-infective Drugs
17.2.4.1. Anti-bacterial Drugs
17.2.4.2. Anti-fungal Drugs
17.2.4.3. Others
17.2.5. Anti-allergy Drugs
17.2.6. Others
17.3. Market Value Forecast, by Indication, 2017-2031
17.3.1. Dry Eye
17.3.2. Glaucoma
17.3.3. Infection/Inflammation
17.3.4. Retinal Disorders
17.3.4.1. Wet AMD
17.3.4.2. Dry AMD
17.3.4.3. Diabetic Retinopathy
17.3.4.4. Others
17.3.5. Allergy
17.3.6. Uveitis
17.3.7. Others
17.4. Market Value Forecast, by Route of Administration, 2017-2031
17.4.1. Topical
17.4.2. Local Ocular (intravitreal)
17.4.3. Others
17.5. Market Value Forecast, by Product Type, 2017-2031
17.5.1. Prescription
17.5.2. OTC
17.6. Market Value Forecast, by Dosage Form, 2017-2031
17.6.1. Eye Drops
17.6.2. Eye Solutions & Suspensions
17.6.3. Capsules & Tablets
17.6.4. Gels
17.6.5. Ointments
17.6.6. Others
17.7. Market Value Forecast, by Distribution Channel, 2017-2031
17.7.1. Hospital Pharmacies
17.7.2. Retail Pharmacies
17.7.3. Online Pharmacies
17.8. Market Value Forecast, by Country/Sub-region, 2017-2031
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Therapeutic Class
17.9.2. By Indication
17.9.3. By Route of Administration
17.9.4. By Product Type
17.9.5. By Dosage Form
17.9.6. By Distribution Channel
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (by tier and size of companies)
18.2. Market Share Analysis, by Company, 2022
18.3. Company Profiles
18.3.1. AbbVie, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Alcon Vision LLC
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. Bausch Health Companies, Inc.
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. Bayer AG
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. Coherus BioSciences
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.5.5. Strategic Overview
18.3.6. F. Hoffmann-La Roche Ltd.
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Novartis Pharmaceuticals Corporation
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Pfizer, Inc.
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. Regeneron Pharmaceuticals, Inc.
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Santen, Inc.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.10.2. Product Portfolio
18.3.10.3. Financial Overview
18.3.10.4. SWOT Analysis
18.3.10.5. Strategic Overview
18.3.11. Sun Pharmaceutical Industries Ltd.
18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.11.2. Product Portfolio
18.3.11.3. Financial Overview
18.3.11.4. SWOT Analysis
18.3.11.5. Strategic Overview
18.3.12. Teva Pharmaceutical Industries Ltd.
18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.12.2. Product Portfolio
18.3.12.3. Financial Overview
18.3.12.4. SWOT Analysis
18.3.12.5. Strategic Overview
List of Tables
Table 01: Global Ophthalmic Drugs Market Volume (Prescriptions in Mn) Forecast, by Dosage Form, 2017-2031
Table 02: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 03: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 04: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 05: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 06: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 07: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 08: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 09: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 10: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 11: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 12: Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 13: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 14: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 15: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 16: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 17: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 18: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 19: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 20: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 21: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 22: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 23: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 24: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 25: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 26: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 27: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 28: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 29: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 30: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 31: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 32: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 33: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 34: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 35: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 36: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 37: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 38: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 39: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 40: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 41: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 42: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 43: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 44: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 45: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 46: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 47: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 48: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 49: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 50: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 51: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 52: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 53: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 54: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 55: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 56: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 57: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 58: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017-2031
Table 59: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-glaucoma Drugs, 2017-2031
Table 60: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-inflammatory Drugs, 2017-2031
Table 61: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Anti-infective Drugs, 2017-2031
Table 62: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
Table 63: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Retinal Disorders, 2017-2031
Table 64: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
Table 65: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017‒2031
Table 66: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Dosage Form, 2017-2031
Table 67: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031
Figure 02: Global Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 03: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-VEGF Agents, 2017-2031
Figure 04: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-glaucoma Drugs, 2017-2031
Figure 05: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-inflammatory Drugs, 2017-2031
Figure 06: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-infective Drugs, 2017-2031
Figure 07: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Anti-allergy Drugs, 2017-2031
Figure 08: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 09: Global Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 10: Global Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 11: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Dry Eye, 2017-2031
Figure 12: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Glaucoma, 2017-2031
Figure 13: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Infection/Inflammation, 2017-2031
Figure 14: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Retinal Disorders, 2017-2031
Figure 15: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Allergy, 2017-2031
Figure 16: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Uveitis 2017-2031
Figure 17: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 18: Global Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 19: Global Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 20: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Topical, 2017-2031
Figure 21: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Local Ocular (intravitreal), 2017-2031
Figure 22: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 23: Global Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 24: Global Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 25: Global Ophthalmic Drugs Market Value (US$ Mn), by Prescription, 2017‒2031
Figure 26: Global Ophthalmic Drugs Market Value (US$ Mn), by OTC, 2017‒2031
Figure 27: Global Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 28: Global Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 29: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Eye Drops, 2017-2031
Figure 30: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Eye Solutions & Suspensions, 2017-2031
Figure 31: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Capsules & Tablets, 2017-2031
Figure 32: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Gels, 2017-2031
Figure 33: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Ointments, 2017-2031
Figure 34: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Others, 2017-2031
Figure 35: Global Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 36: Global Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 37: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 38: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 39: Global Ophthalmic Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
Figure 40: Global Ophthalmic Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 41: Global Ophthalmic Drugs Market Attractiveness Analysis, by Region, 2023-2031
Figure 42: North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 43: North America Ophthalmic Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 44: North America Ophthalmic Drugs Market Attractiveness Analysis, by Country, 2023-2031
Figure 45: North America Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031
Figure 46: North America Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 47: North America Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 48: North America Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 49: North America Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 50: North America Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 51: North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 52: North America Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 53: North America Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 54: North America Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 55: North America Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 56: North America Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 57: Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 58: Europe Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 59: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 60: Europe Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031
Figure 61: Europe Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 62: Europe Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 63: Europe Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 64: Europe Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 65: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 66: Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 67: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 68: Europe Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 69: Europe Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 70: Europe Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 71: Europe Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 72: Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 73: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 74: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 75: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031
Figure 76: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 77: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 78: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 79: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 80: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 81: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 82: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 83: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 84: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 85: Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 86: Asia Pacific Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 87: Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 88: Latin America Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 89: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 90: Latin America Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class, 2022 and 2031
Figure 91: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 92: Latin America Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 93: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 94: Latin America Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 95: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 96: Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 97: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 98: Latin America Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 99: Latin America Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 100: Latin America Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 101: Latin America Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 102: Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017-2031
Figure 103: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 104: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 105: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Therapeutic Class 2022 and 2031
Figure 106: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Therapeutic Class, 2023-2031
Figure 107: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Indication, 2022 and 2031
Figure 108: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Indication, 2023-2031
Figure 109: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
Figure 110: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Route of Administration, 2023-2031
Figure 111: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2022 and 2031
Figure 112: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 113: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Dosage Form, 2022 and 2031
Figure 114: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, Dosage Form, 2023-2031
Figure 115: Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 116: Middle East & Africa Ophthalmic Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ophthalmic Drugs Market
